London, UK; Manchester, UK, 20 November 2006 – Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, and The University of Manchester have entered into an agreement with AstraZeneca to establish a clinical pharmacology biomarker research and discovery collaboration.
